Arax Advisory Partners’s Cullinan Oncology CGEM Stock Holding History

Arax Advisory Partners’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.97K	Buy	350 +178	+103%	+$2.29K	﹤0.01%	2783
2025 Q4	$1.78K	Sell	172 -1,268	-88%	-$11.4K	﹤0.01%	3304
2025 Q3	$8.54K	Buy	+1,440	New	+$10.5K	﹤0.01%	2667
2024 Q4	–	Sell	-7	Closed	-$118	–	2485
2024 Q3	$118	Hold	7	–	–	﹤0.01%	2549
2024 Q2	$123	Buy	+7	New	+$149	﹤0.01%	2477

Other funds holding CGEM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Blue Owl Capital Holdings New York $369M AUM 78.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return